Press Releases March 29, 2026 08:00 PM

Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

Synergy CHC Corp. schedules earnings release and conference call for Q4 and full year 2025 results

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
SNYR

Synergy CHC Corp., a consumer health and wellness company, announced its updated date for releasing fourth quarter and full year 2025 financial results on April 1, 2026, prior to market open. The company will host a live conference call with executives to discuss the results, accessible via webcast and phone. Synergy's leading brands include FOCUSfactor and Flat Tummy, with established distribution across major retailers and ongoing market expansion.

Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call
SNYR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release for Q4 and full year 2025 scheduled for April 1, 2026 before market open.
  • Conference call with CEO and CFO to discuss financial results will be held on the release day.
  • Synergy’s flagship brands FOCUSfactor and Flat Tummy have broad retail distribution and are expanding markets internationally.

WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading.

In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada, Mexico and the U.K. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. The brand continues to accelerate growth, penetrating new markets both domestically and internationally, with recent retail wins across mass, grocery, pharmacy, convenience, and wholesale channels poised to drive meaningful gains. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management.

Investor Relations

Gateway Group
Cody Slach, Greg Robles
949.574.3860
[email protected]


Risks

  • Potential market volatility around the earnings release due to financial performance uncertainties.
  • Risks associated with international market expansion and new retail channel penetration.
  • Dependence on continued consumer demand in the competitive health and wellness sector.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026